Loading quotes...
Forecast
The analysts' average price target is €18.66 (-22.70%). The median is €18.66 (-22.70%).
| Buy |
3 |
| Hold |
8 |
| Sell |
1 |
News Go to news feed
Amphastar pins growth on BAQSIMI and its own development pipeline
At the Wells Fargo healthcare conference, Amphastar outlined a business plan centered on BAQSIMI, a broader pipeline and resolving pricing and manufacturing issues. The company confirms mid- to high-single-digit revenue growth for 2026 and expects peak BAQSIMI sales of $250–275 million, with a 340B double-discount issue to be resolved by Q3/Q4 2026. Amphastar is modernizing its IMS facility after an FDA warning letter, is keeping capex plans unchanged, and plans to finance four early-stage programs from cash flow, with launches such as AMP-004 and AMP-018 supporting a stronger 2027. » More on de.investing.com
Amphastar beats revenue forecasts in Q2 2026, shares rise in after-hours trading
Amphastar reported Q2 2026 revenue of $183.9 million versus expected $179.71 million and raised gross margin to 51%. Growth was driven mainly by newer products such as Ipratropiumbromid ($8.4 million) and stronger branded and generic sales, while glucagon and some older products declined. The company reaffirmed its full-year guidance for mid- to high-single-digit revenue growth but noted increased costs to remediate an FDA warning letter at the IMS facility. The stock reacted positively, rising about 6.2% in after-hours trading. » More on de.investing.com
Amphastar signs new employment contracts for executives Jacob Liawatidewi and Rong Zhou
Amphastar has entered into new one‑year contracts with automatic renewal for Jacob Liawatidewi and Rong Zhou. Liawatidewi will receive a base salary of $525,800 and a performance‑based cash bonus (target 55%); Zhou will receive $590,000 and a bonus (target 53%). Both are eligible for equity‑based incentives; if terminated without cause they would receive severance equal to two times base salary plus the average bonus, and unvested stock options would be partially accelerated. The company also reported Q4 2025 results in which revenue and adjusted earnings per share missed expectations, after which an analyst cut the price target from $34 to $30. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 161.14m | 8.89% |
| Gross profit | 81.9m | 11.61% |
| Net profit | 26.59m | 1.01% |
| EBITDA | 54.03m | 2.95% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €1.02bn |
Number of shares | 42.54m |
52-week high/low | €26.23 - €14.79 |
| Dividends | No |
Beta | 0.93 |
P/E ratio | 15.59 |
PEG ratio | -0.41 |
P/B ratio | 1.54 |
P/S ratio | 1.58 |
Company profile
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
| Name | Amphastar Pharmaceuticals |
| CEO | Yongfeng Zhang |
| Headquarters | Rancho Cucamonga,
ca USA |
| Website | |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| IPO | 25/06/2014 |
| Employees | 1,976 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | AMPH |
Frankfurt | 29A.F |
Düsseldorf | 29A.DU |
München | 29A.MU |